ChromaDex

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Wednesday, March 6, 2024

ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results.
  • Maintained positive operating cash flows for a fourth consecutive quarter, ending with $27.3 million in cash and no debt.
  • Additionally, the fourth quarter marked an important milestone with the company achieving positive net income,” said Rob Fried, ChromaDex Chief Executive Officer.
  • ChromaDex ended fiscal year 2023 with $27.3 million in cash and cash equivalents and no debt.

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

Retrieved on: 
Wednesday, February 21, 2024

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m.
  • ET to discuss its financial results for the fourth quarter, which ended December 31, 2023.
  • The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
  • ChromaDex management will host an investor conference call to discuss fourth quarter 2023 results and provide a general business update on Wednesday, March 6, at 4:30 p.m.

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024

Retrieved on: 
Monday, February 5, 2024

ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend this live event.

Key Points: 
  • ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend this live event.
  • The presentation will feature ChromaDex’s Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber.
  • Topics to be covered will include the latest investor presentation followed by a live Q&A.
  • Investors interested in participating in this event will need to register using the link below.

ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference

Retrieved on: 
Friday, January 26, 2024

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners 2024 Investor Select Conference.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners 2024 Investor Select Conference.
  • Mr. Fried and Mrs. Gerber will participate in virtual one-on-one meetings throughout the event on Thursday, February 1, 2024.
  • To arrange a meeting with the ChromaDex management team, please contact Lytham Partners at [email protected] or register for the event at https://lythampartners.com/select2024invreg/ .
  • For additional information on ChromaDex, visit www.chromadex.com , and for details on investor relations, please visit www.investors.chromadex.com .

ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®

Retrieved on: 
Wednesday, December 20, 2023

In a gesture of gratitude and further support US troops, ChromaDex has launched an exclusive program that offers Tru Niagen products to active and veteran Military Service Members.

Key Points: 
  • In a gesture of gratitude and further support US troops, ChromaDex has launched an exclusive program that offers Tru Niagen products to active and veteran Military Service Members.
  • "We are honored that Tru Niagen will play a role in the health and wellness of our troops,” said Rob Fried, CEO of ChromaDex.
  • For more information about Tru Niagen’s military discount program, please visit https://discover.truniagen.com/military/ .
  • If you are an active or veteran US Military Service Member interested in purchasing Tru Niagen, please email [email protected] for more details.

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

Retrieved on: 
Thursday, November 30, 2023

These results build upon previous research led by Dr. Tzoulis ( Cell Metabolism ) and showcase that supplementation with Niagen NR may be a therapeutic strategy for PD, pending further research.

Key Points: 
  • These results build upon previous research led by Dr. Tzoulis ( Cell Metabolism ) and showcase that supplementation with Niagen NR may be a therapeutic strategy for PD, pending further research.
  • Current treatment options are limited, and there is a pressing need for innovative approaches to manage the effects of this debilitating neurodegenerative disorder.
  • This study establishes the short-term safety of 3,000 mg NR daily and allows the clinical community to explore high-dose options in future therapeutic trials.
  • Notably, all of Prof. Tzoulis’ clinical research is academically-driven and based largely on public funding.

Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients

Retrieved on: 
Wednesday, November 15, 2023

The promising results demonstrate that long-term supplementation with Niagen NR effectively increased whole blood NAD+ levels up to fourfold, improved coordination, and enhanced eye movement while maintaining biomarkers of stable liver and kidney function in Ataxia Telangiectasia (AT) patients.

Key Points: 
  • The promising results demonstrate that long-term supplementation with Niagen NR effectively increased whole blood NAD+ levels up to fourfold, improved coordination, and enhanced eye movement while maintaining biomarkers of stable liver and kidney function in Ataxia Telangiectasia (AT) patients.
  • AT is a rare, inherited neurodegenerative disorder characterized by premature aging, cerebellar degeneration, immunodeficiency, and cancer predisposition.
  • View the full release here: https://www.businesswire.com/news/home/20231115900463/en/
    Newly published phase II clinical study demonstrates that supplementation with Niagen, patented nicotinamide riboside (NR), elevates NAD+ up to fourfold, improving motor coordination and eye movement in Ataxia Telangiectasia (AT) patients (Graphic: Business Wire)
    Building on a growing body of research, this is the second published study ( Veenhuis et al.
  • This growing body of research is promising as it demonstrates that NR supplementation may be a potential therapeutic strategy for AT patients.”

Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+

Retrieved on: 
Tuesday, December 12, 2023

SAN DIEGO, Dec. 12, 2023 /PRNewswire/ -- Neurohacker Collective, an acclaimed American science team that has been formulating advanced nutritional supplements since 2015, has just created an NAD+ supplement called Qualia NAD+ that tackles the challenge of boosting NAD+ levels in aging Americans.*

Key Points: 
  • "We look forward to this partnership with Neurohacker Collective as the unique Qualia NAD+ formulation will expand the positive effects of our precious Niagen to more people worldwide.
  • "*
    In the last decade, science has discovered countless links between healthy aging, and maintaining high levels of the molecule NAD+.
  • This is because NAD+ plays an essential role in vital cellular processes including mitochondrial function, cellular energy production, and DNA repair.
  • "*
    Qualia NAD+ became available through neurohacker.com beginning in early October, with an expanded product launch anticipated in additional channels shortly.

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023

Retrieved on: 
Thursday, November 9, 2023

ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend these live events.

Key Points: 
  • ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend these live events.
  • The presentations will feature Rob Fried, Chief Executive Officer, and Brianna Gerber, Chief Financial Officer.
  • Topics to be covered will include the latest investor presentation followed by a live Q&A.
  • Investors interested in participating in either of these events will need to register using the links below.

ChromaDex Corporation Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 8, 2023

ChromaDex Corp. (NASDAQ: CDXC) today announced financial results for the third quarter of 2023.

Key Points: 
  • ChromaDex Corp. (NASDAQ: CDXC) today announced financial results for the third quarter of 2023.
  • Strong gross margin of 61.4%, an increase of 160 basis points, compared to 59.8% from the prior year quarter.
  • Adjusted EBITDA, a non-GAAP measure, was a positive $0.5 million, a $1.7 million improvement from the prior year quarter.
  • In October 2023, Zesty Paws, a prominent name in pet supplements, partnered with ChromaDex to launch a Healthy Aging NAD+ Precursor supplement for pets, featuring Niagen®.